IJCS | Volume 33, Nº2, March / April 2020

117 1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-41. 2. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2012 - Guias de avaliaç o e tratamento. 2a ed. Rio de Janeiro; 2012. 3. World Health Organization.(WHO). Global report on psoriasis.2016. [ Cited in 2018 23 dez] [ Available in: http://www.who.int/iris/ handle/10665/204417] 4. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-35. 5. Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol. 2011;146(1):9-15. 6. Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat. 2006;17(6):343-52. 7. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol. 2005;17(4):406-12. 8. Prinz JC. Psoriasis vulgaris--a sterile antibacterial skin reactionmediated by cross-reactive T cells?An immunological viewof the pathophysiology of psoriasis. Clin Exp Dermatol. 2001;26(4):326-32. 9. Pattison E, Harrison BJ, Griffiths CE, SilmanAJ, Bruce IN. Environmental risk factors for the development of psoriatic arthritis: results from a case- control study. Ann Rheum Dis. 2008;67(5):672-6. 10. Ko HC, Jwa SW, Song M, Kim MB, Kwon KS. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol. 2010;37(10):894-9. 11. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304-14. 12. Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63(6):1058-69. 13. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11-12):1318-27. 14. Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94(6):627-34. 15. Carneiro S,AzevedoVF, Bonfiglioli R, Ranza R, Goncalves CR, Keiserman M, et al. Recommendations for the management and treatment of psoriatic arthritis. Rev Bras Reumatol. 2013;53(3):227-41. 16. Mota LM, Brenol CV, Pollak DF, Pinheiro GR, Laurindo IM, Pereira IA, et al. Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides. Rev Bras Reumatol. 2015; 55(3):281-309. 17. Samarasekera EJ, Neilson JM,WarrenRB, ParnhamJ, SmithCH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340-6. 18. Sterry W, Strober BE, Menter A, International Psoriasis C. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649-55. 19. Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013; 27(Suppl 3):12–29. 20. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann RheumDis. 2014; 74(2), 326–32. 21. Samarasekera EJ, Neilson JM,WarrenRB, ParnhamJ, SmithCH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340-6. 22. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-41. 23. Skiveren J, Philipsen P, Therming G. Patients with psoriasis have insufficient knowledge of their risk of atherothrombotic disease and metabolic syndrome. Clin Exp Dermatol. 2015;40(6):600-4. 24. TaylorW, GladmanD, Helliwell P, MarchesoniA, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of newcriteria from a large international study. Arthritis Rheum. 2006;54(8):2665-73. 25. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. 26. Faludi AA, Izar MC, Saraiva JF, Chacra AP, Bianco HT, Afiune Neto A, et al. Atualizaç o da Diretriz Brasileira de Dislipidemias e Prevenç o da Aterosclerose – 2017. Arq Bras Cardiol. 2017;109(2 Suppl 1):1-76. 27. Associaç o Brasileira para o Estudo da Obesidade e da Síndrome Metab lica. Diretrizes brasileiras de obesidade 4a ed . S o Paulo;2016. p.1-186. 28. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28. 29. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(12):1729-35. 30. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433-42; discussion 42-3. 31. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84-91. 32. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-35. 33. Goldenstein-Schainberg C, Favarato MH, Ranza R. Conceitos atuais e relevantes sobre artrite psoriásica. Rev Bras Reumatol. 2012;52(1): 98-106. 34. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411-8. 35. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al.A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.Ann Rheum Dis. 2012;71(3):319-26. 36. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165(9):978–84. 37. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J. 1994;70(830):863-70. 38. Eder L, Gladman DD.Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther AdvMusculoskelet Dis. 2015;7(5):187-95. References Campos et al. Psoriatic arthritis and cardiovascular risk Int J Cardiovasc Sci. 2020; 33(2):112-118 Original Article